Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR84 | Q9NQS5 | 8/20 | 0.66 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.66 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.47 |
| ▸ | FAAH | O00519 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | LCK | P06239 | 1/20 | 0.42 |
| ▸ | PPARD | Q03181 | 1/20 | 0.42 |
| ▸ | ZDHHC20 | Q5W0Z9 | 1/20 | 0.42 |
| ▸ | ZDHHC2 | Q9UIJ5 | 1/20 | 0.42 |
| ▸ | GRIK1 | P39086 | 1/20 | 0.41 |
| ▸ | GRIK2 | Q13002 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17302563 | 1.00 | GPR84 (0.66) | GPR84FFAR1FFAR4FAAHL3MBTL1 | |
| SCHEMBL17302570 | 0.91 | GPR84 (0.58) | GPR84FFAR1FFAR4FAAHL3MBTL1 | |
| SCHEMBL17199810 | 0.87 | GPR84 (0.47) | GPR84FFAR1FFAR4L3MBTL1 | |
| SCHEMBL17368055 | 0.86 | GRIK1 (0.50) | GPR84FFAR1FFAR4GRIK1GRIK2 | |
| SCHEMBL29138696 | 0.84 | FFAR4 (0.70) | GPR84FFAR1FFAR4PPARD | |
| SCHEMBL7854619 | 0.84 | FFAR4 (0.70) | GPR84FFAR1FFAR4PPARD | |
| SCHEMBL26039947 | 0.83 | GPR84 (0.47) | GPR84FFAR1FFAR4L3MBTL1 | |
| SCHEMBL27871631 | 0.83 | GPR84 (0.88) | GPR84FFAR1FFAR4FAAHMAPT | |
| SCHEMBL28815899 | 0.83 | GPR84 (0.88) | GPR84FFAR1FFAR4FAAHMAPT | |
| SCHEMBL25399220 | 0.83 | FFAR4 (0.67) | GPR84FFAR1FFAR4PPARD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11433144-B2 | Biodegradable lipids for delivery of nucleic acids | TRANSLATE BIO, INC. (US) | 2022-09-06 | — | — | US | disclosed |
| EP-3587409-B1 | BIODEGRADABLE LIPIDS FOR DELIVERY OF NUCLEIC ACIDS | TRANSLATE BIO INC (US) | 2022-06-01 | — | — | EP | disclosed |
| US-20210369866-A1 | BIODEGRADABLE LIPIDS FOR DELIVERY OF NUCLEIC ACIDS | TRANSLATE BIO, INC. | 2021-12-02 | — | — | US | disclosed |
| US-10912844-B2 | Biodegradable lipids for delivery of nucleic acids | TRANSLATE BIO, INC. (US) | 2021-02-09 | — | — | US | disclosed |
| US-20200222558-A1 | BIODEGRADABLE LIPIDS FOR DELIVERY OF NUCLEIC ACIDS | RANA THERAPEUTICS, INC. | 2020-07-16 | — | — | US | disclosed |
| EP-3148552-B1 | BIODEGRADABLE LIPIDS FOR DELIVERY OF NUCLEIC ACIDS | TRANSLATE BIO INC (US) | 2019-07-31 | — | — | EP | disclosed |
| US-10293057-B2 | Biodegradable lipids for delivery of nucleic acids | TRANSLATE BIO, INC. (US) | 2019-05-21 | — | — | US | disclosed |
| US-10286082-B2 | Biodegradable lipids for delivery of nucleic acids | TRANSLATE BIO, INC. (US) | 2019-05-14 | — | — | US | disclosed |
| US-10286083-B2 | Biodegradable lipids for delivery of nucleic acids | TRANSLATE BIO, INC. (US) | 2019-05-14 | — | — | US | disclosed |
| US-20180272004-A1 | Biodegradable Lipids for Delivery of Nucleic Acids | TRANSLATE BIO, INC. | 2018-09-27 | — | — | US | disclosed |
| US-20180272003-A1 | Biodegradable Lipids for Delivery of Nucleic Acids | TRANSLATE BIO, INC. | 2018-09-27 | — | — | US | disclosed |
| US-20180272005-A1 | Biodegradable Lipids for Delivery of Nucleic Acids | TRANSLATE BIO, INC. (US) | 2018-09-27 | — | — | US | disclosed |
| US-20180272002-A1 | Biodegradable Lipids for Delivery of Nucleic Acids | TRANSLATE BIO, INC. | 2018-09-27 | — | — | US | disclosed |
| US-10022455-B2 | Biodegradable lipids for delivery of nucleic acids | TRANSLATE BIO, INC. (US) | 2018-07-17 | — | — | US | disclosed |
| US-10022455-B2 | Biodegradable lipids for delivery of nucleic acids | TRANSLATE BIO, INC. (US) | 2018-07-17 | — | — | US | disclosed |
| US-20170246319-A1 | BIODEGRADABLE LIPIDS FOR DELIVERY OF NUCLEIC ACIDS | SHIRE HUMAN GENETIC THERAPIES, INC. | 2017-08-31 | — | — | US | disclosed |
| US-20170246319-A1 | BIODEGRADABLE LIPIDS FOR DELIVERY OF NUCLEIC ACIDS | SHIRE HUMAN GENETIC THERAPIES, INC. | 2017-08-31 | — | — | US | disclosed |
| US-20170246319-A1 | BIODEGRADABLE LIPIDS FOR DELIVERY OF NUCLEIC ACIDS | SHIRE HUMAN GENETIC THERAPIES, INC. | 2017-08-31 | — | — | US | disclosed |
| EP-3148552-A2 | BIODEGRADABLE LIPIDS FOR DELIVERY OF NUCLEIC ACIDS | Shire Human Genetic Therapies, Inc. (US) | 2017-04-05 | — | — | EP | disclosed |
| WO-2015184256-A2 | BIODEGRADABLE LIPIDS FOR DELIVERY OF NUCLEIC ACIDS | SHIRE HUMAN GENETIC THERAPIES, INC. (US) | 2015-12-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (13 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10022455-B2 | Biodegradable lipids for delivery of nucleic acids | LIPA, SLC67A1, SREBF1 | GPR84 2307/4885FFAR1 545/4885FFAR4 1417/4885 |
| US-20170246319-A1 | BIODEGRADABLE LIPIDS FOR DELIVERY OF NUCLEIC ACIDS | LIPA, SLC67A1, SREBF1 | GPR84 2307/4885FFAR1 545/4885FFAR4 1417/4885 |
| US-20210369866-A1 | BIODEGRADABLE LIPIDS FOR DELIVERY OF NUCLEIC ACIDS | LIPA, SLC67A1, SREBF1 | GPR84 2307/4885FFAR1 545/4885FFAR4 1417/4885 |
| US-10286083-B2 | Biodegradable lipids for delivery of nucleic acids | LIPA, SLC67A1, SREBF1 | GPR84 2307/4885FFAR1 545/4885FFAR4 1417/4885 |
| US-10293057-B2 | Biodegradable lipids for delivery of nucleic acids | LIPA, SLC67A1, SREBF1 | GPR84 2307/4885FFAR1 545/4885FFAR4 1417/4885 |
| US-20180272004-A1 | Biodegradable Lipids for Delivery of Nucleic Acids | LIPA, SLC67A1, SREBF1 | GPR84 2307/4885FFAR1 545/4885FFAR4 1417/4885 |
| US-11433144-B2 | Biodegradable lipids for delivery of nucleic acids | LIPA, SLC67A1, SREBF1 | GPR84 2307/4885FFAR1 545/4885FFAR4 1417/4885 |
| US-20180272002-A1 | Biodegradable Lipids for Delivery of Nucleic Acids | LIPA, SLC67A1, SREBF1 | GPR84 2230/4885FFAR1 519/4885FFAR4 1339/4885 |
| US-20180272005-A1 | Biodegradable Lipids for Delivery of Nucleic Acids | LIPA, SLC67A1, SREBF1 | GPR84 2307/4885FFAR1 545/4885FFAR4 1417/4885 |
| US-10912844-B2 | Biodegradable lipids for delivery of nucleic acids | LIPA, SLC67A1, SREBF1 | GPR84 2307/4885FFAR1 545/4885FFAR4 1417/4885 |
| US-10286082-B2 | Biodegradable lipids for delivery of nucleic acids | LIPA, SLC67A1, SREBF1 | GPR84 2307/4885FFAR1 545/4885FFAR4 1417/4885 |
| US-20180272003-A1 | Biodegradable Lipids for Delivery of Nucleic Acids | LIPA, SLC67A1, SREBF1 | GPR84 2307/4885FFAR1 545/4885FFAR4 1417/4885 |
| US-20200222558-A1 | BIODEGRADABLE LIPIDS FOR DELIVERY OF NUCLEIC ACIDS | LIPA, SLC67A1, SREBF1 | GPR84 2307/4885FFAR1 545/4885FFAR4 1417/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.